Safety reporting and labeling
Once a drug is on the market, the company has to collect adverse event information and report it on timelines that depend on how serious and unexpected the events are. Signals emerging from those reports, from studies, or from the published literature can lead to labeling changes, and in some situations a brand manufacturer can strengthen safety information before the FDA approves the change. Some products come with risk management programs that restrict how they are prescribed or dispensed. Missed or late reports are a frequent inspection finding. The systems that route information from customer service, sales, and medical affairs to the safety team are where problems usually start.
Manufacturing and the supply chain
Drugs must be made under current good manufacturing practice, and changes to a facility, process, or supplier may require notice to the FDA or its prior approval, depending on their significance. Using a contract manufacturer does not move responsibility away from the application holder, so quality agreements and real oversight matter. Federal supply chain rules require many prescription drugs to be traced through distribution, and trading partners are expected to verify one another. Shortages and discontinuations of certain products can carry notification duties as well. Each of these runs on its own process and its own clock.
Where a review begins
A pharmaceutical regulatory compliance review is usually prompted by an inspection, a partner's audit, an acquisition, or a concern raised inside the company. We start by understanding the product portfolio and which obligations attach to each product. We then look at how safety information, manufacturing changes, and labeling decisions are documented and approved. When a gap is found, we discuss whether it calls for a report to the agency and how to correct it. Technical judgments belong to your regulatory and quality staff, and we help make sure the legal side of each decision holds together.
